INDEMNITY AGREEMENTIndemnity Agreement • February 25th, 2015 • HTG Molecular Diagnostics, Inc • Laboratory analytical instruments • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
Via Email Only (smcmeans@htgmolecular.com)Release Agreement • February 25th, 2015 • HTG Molecular Diagnostics, Inc • Laboratory analytical instruments
On behalf of HTG Molecular Diagnostics, Inc. (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated January 12, 2012 (the “Prior Agreement”), as provided in Section 12 below.
Via Email Only (jlubniewski@htgmolecular.com)HTG Molecular Diagnostics, Inc • February 25th, 2015 • Laboratory analytical instruments
On behalf of HTG Molecular Diagnostics, Inc. (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated March 30, 2011 (the “Prior Agreement”), as provided in Section 12 below.
HTG MOLECULAR DIAGNOSTICS, INC. WARRANT TO PURCHASE STOCKHTG Molecular Diagnostics, Inc • February 25th, 2015 • Laboratory analytical instruments • Delaware
This Warrant is being issued as one of a series of warrants (the “Warrants”) pursuant to the terms of that certain Note and Warrant Purchase Agreement, dated December 30, 2014, by and among the Company and the persons and entities listed on the Schedule of Investors thereto (the “Purchase Agreement”). The Holder and the Company shall be bound by all the terms, conditions and provisions of the Purchase Agreement. Without limiting the generality of the foregoing, this Warrant may be terminated prior to the end of the Exercise Period pursuant to Section 2.1 of the Purchase Agreement. Unless otherwise specified, all capitalized terms used but not defined in this Warrant shall have the meanings ascribed thereto in the form of Subordinated Convertible Promissory Note attached as Exhibit B to the Purchase Agreement (“Convertible Note”). As used in this Warrant, the “Note” means, collectively (if applicable), the one or more Convertible Note(s) issued to Holder pursuant to the Purchase Agreeme
HTG MOLECULAR DIAGNOSTICS, INC. NOTE AND WARRANT PURCHASE AGREEMENTNote and Warrant Purchase Agreement • February 25th, 2015 • HTG Molecular Diagnostics, Inc • Laboratory analytical instruments • Delaware
THIS NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is made as of December 30, 2014 (the “Effective Date”) by and among HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (the “Company”), and the entities and persons executing signature pages hereto (each referred to herein as a “Stockholder” and collectively as the “Stockholders”).
